Lung Cancer Treatment Advances in 2022

References

• Howlader N, Noone A, Me K, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2016. Natl Cancer Institut. 2019;1
   Google Scholar
• Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824–1832. doi:10.1001/jamaoncol.2021.4932.
   PubMed Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi:10.1056/NEJMoa1916623.
   PubMed Web of Science ®Google Scholar
• Desai A, Gyawali B. Fall in US cancer death rates: Time to pop the champagne? EClinicalMedicine. 2020;19:100279. doi:10.1016/j.eclinm.2020.100279.
   PubMedGoogle Scholar
• Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non–small-cell lung cancer. J Clin Oncol. 2022;40(6):546–555. doi:10.1200/JCO.21.01589.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985. doi:10.1056/NEJMoa2202170.
   PubMed Web of Science ®Google Scholar
• Qiu F, Fan J, Shao M, Yao J, Zhao L, Zhu L, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): a randomized, single center, two-arm phase II trial. Am Soc Clin Oncol. 2022;
   Google Scholar
• Provencio-Pulla M, Nadal E, Larriba JLG, Martinez-Marti A, Bernabé R, Bosch-Barrera J, et al. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. Am Soc Clin Oncol. 2022;
   Google Scholar
• Brahmer JR, Lee J-S, Ciuleanu T-E, Caro RB, Nishio M, Urban L, et al. Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): results from CheckMate 227. JCO. 2022;40(17_suppl):LBA9025. doi:10.1200/JCO.2022.40.17_suppl.LBA9025.
   Web of Science ®Google Scholar
• Paz-Ares LG, Ciuleanu T-E, Cobo-Dols M, Bennouna J, Cheng Y, Mizutani H, et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. JCO. 2022;40(17_suppl):LBA9026. doi:10.1200/JCO.2022.40.17_suppl.LBA9026.
   Web of Science ®Google Scholar
• Akinboro O, Vallejo JJ, Nakajima EC, Ren Y, Mishra-Kalyani PS, Larkins EA, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. JCO. 2022;40(16_suppl):9000. doi:10.1200/JCO.2022.40.16_suppl.9000.
   Google Scholar
• Lena H, Monnet I, Bylicki O, Audigier-Valette C, Falchero L, Vergnenegre A, GFPC, et al. Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study). JCO. 2022;40(16_suppl):9011. doi:10.1200/JCO.2022.40.16_suppl.9011.
   Google Scholar
• Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy—lung-MAP S1800A. J Clin Oncol. 2022;40(21):2295–2306. doi:10.1200/JCO.22.00912.
   PubMed Web of Science ®Google Scholar
• Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–625. doi:10.1200/JCO.21.01626.
   PubMed Web of Science ®Google Scholar
• Sankar K, Gadgeel SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20(8):647–661. doi:10.1080/14737140.2020.1787156.
   PubMed Web of Science ®Google Scholar
• Shu CA, Goto K, Ohe Y, Besse B, Lee S-H, Wang Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2. JCO. 2022;40(16_suppl):9006. doi:10.1200/JCO.2022.40.16_suppl.9006.
   Web of Science ®Google Scholar
• Goldman JW, Horinouchi H, Cho BC, Tomasini P, Dunbar M, Hoffman D, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). JCO. 2022;40(16_suppl):9013. doi:10.1200/JCO.2022.40.16_suppl.9013.
   Web of Science ®Google Scholar
• Yu HA, Tan DS-W, Smit EF, Spira AI, Soo RA, Nguyen D, et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). JCO. 2022;40(16_suppl):9007. doi:10.1200/JCO.2022.40.16_suppl.9007.
   Google Scholar
• Krebs M, Spira AI, Cho BC, Besse B, Goldman JW, Janne PA, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study. JCO. 2022;40(16_suppl):9008. doi:10.1200/JCO.2022.40.16_suppl.9008.
   Web of Science ®Google Scholar
• Camidge DR, Bar J, Horinouchi H, Goldman JW, Moiseenko FV, Filippova E, et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). JCO. 2022;40(16_suppl):9016. doi:10.1200/JCO.2022.40.16_suppl.9016.
   Web of Science ®Google Scholar
• Spira AI, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. JCO. 2022;40(16_suppl):9002. doi:10.1200/JCO.2022.40.16_suppl.9002.
   Web of Science ®Google Scholar
• Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–131. doi:10.1056/NEJMoa2204619.
   PubMed Web of Science ®Google Scholar
• Sabari JK, Spira AI, Heist RS, Janne PA, Pacheco JM, Weiss J, et al. Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial. JCO. 2022;40(17_suppl):LBA9009. doi:10.1200/JCO.2022.40.17_suppl.LBA9009.
   Web of Science ®Google Scholar
• Rudin CM, Liu SV, Lu S, Soo RA, Hong MH, Lee J-S, et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). JCO. 2022;40(17_suppl):LBA8507. doi:10.1200/JCO.2022.40.17_suppl.LBA8507.
   Web of Science ®Google Scholar
• Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, HLX10-005-SCLC301 Investigators, et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. JCO. 2022;40(16_suppl):8505. doi:10.1200/JCO.2022.40.16_suppl.8505.
   Web of Science ®Google Scholar
• Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372–1387. doi:10.1158/2159-8290.CD-19-0582.
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36(23):2386–2394. doi:10.1200/JCO.2018.77.7672.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Cummings AL, Mendenhall MA, Velez MA, Babu S, Johnson TT, et al. Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC). JCO. 2022;40(16_suppl):8517. doi:10.1200/JCO.2022.40.16_suppl.8517.
   Web of Science ®Google Scholar
• Ma S, He Z, Wang L, Wu Y, Yang S, Chen H, et al. Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial. JCO. 2022;40(16_suppl):8516. doi:10.1200/JCO.2022.40.16_suppl.8516.
   Web of Science ®Google Scholar